{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01605383",
      "OrgStudyIdInfo": {
        "OrgStudyId": "XCEL-MT-10-01"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2010-023998-18",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Banc de Sang i Teixits",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head",
      "OfficialTitle": "A Pilot Clinical Trial of \"ex Vivo\" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue (XCEL-MT-OSTEO- ALPHA) in Osteonecrosis of the Femoral Head"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 5, 2015",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 11, 2018",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 27, 2019",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "May 22, 2012",
      "StudyFirstSubmitQCDate": "May 23, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 24, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "January 15, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 21, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Banc de Sang i Teixits",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Ministerio de Sanidad, Servicios Sociales e Igualdad",
            "CollaboratorClass": "OTHER_GOV"
          },
          {
            "CollaboratorName": "Ministerio de Ciencia e Innovaci√≥n, Spain",
            "CollaboratorClass": "OTHER_GOV"
          },
          {
            "CollaboratorName": "European Regional Development Fund",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The present study evaluates the effect of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head in comparison to the standard treatment of isolated core decompression.\n\nXCEL-MT-OSTEO-ALPHA is a tissue engineering product composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue.\n\nThe working hypothesis proposes that the tissue engineering is a valid and useful technique to achieve bone regeneration, avoiding the progression to collapse of the femoral head.",
      "DetailedDescription": "Prospective, open-label with blinded assessor, randomized, parallel, single-dose phase I-II clinical trial in which 24 patients affected with osteonecrosis of the femoral head ARCO grade I or II will enter the trial with the primary objective of assessing the feasibility and safety of \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in osteonecrosis of the femoral head. Secondary objectives are to assess the efficacy of the implantation by imaging (magnetic resonance imaging) and clinical questionnaires (pain by visual analogue scale, quality of life by SF-36 and WOMAC Index).\n\nPatients will be randomized to one of the two treatment arms (core decompression and the tissue engineering product composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue or the standard treatment of isolated core decompression). Thereafter, patients will be followed for 12 months."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Avascular Necrosis of Femur Head"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Avascular Necrosis of Femur Head",
          "Osteonecrosis of the hip",
          "Osteonecrosis of the femoral head",
          "Mesenchymal Stem Cells",
          "Bone marrow",
          "Tissue engineering",
          "Bone Diseases",
          "Musculoskeletal Diseases"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "23",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "XCEL-MT-OSTEO-ALPHA",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: XCEL-MT-OSTEO-ALPHA"
              ]
            }
          },
          {
            "ArmGroupLabel": "Standard Treatment",
            "ArmGroupType": "Sham Comparator",
            "ArmGroupDescription": "Isolated core decompression",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: Standard treatment"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "XCEL-MT-OSTEO-ALPHA",
            "InterventionDescription": "Core decompression plus XCEL-MT-OSTEO-ALPHA",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "XCEL-MT-OSTEO-ALPHA"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Standard treatment",
            "InterventionDescription": "Isolated core decompression",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Standard Treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head",
            "PrimaryOutcomeDescription": "Safety will be assessed by collecting adverse events throughout the experimental phase, which includes a follow-up of 12 months",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head",
            "PrimaryOutcomeDescription": "Feasibility will be measured by assessing the percentage of patients to which bone marrow puncture is made are thereafter treated and by checking the cascade of procedures to confirm the global process is viable.",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Bone regeneration by measuring the necrotic angle using the modified Kerboul method",
            "SecondaryOutcomeDescription": "The necrotic angle will be measured using imaging procedures (magnetic resonance imaging MRI).",
            "SecondaryOutcomeTimeFrame": "6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Dynamic changes of signal intensity",
            "SecondaryOutcomeDescription": "Dynamic changes of signal intensity after Gd enhancement in the necrotic areas of the femoral head",
            "SecondaryOutcomeTimeFrame": "6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Clinical outcomes (pain) by Visual Analogue Scale (VAS)",
            "SecondaryOutcomeDescription": "Pain measurement by VAS",
            "SecondaryOutcomeTimeFrame": "7 days and at 3, 6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Clinical outcomes (SF-36)",
            "SecondaryOutcomeDescription": "This clinical outcome will measure the quality of life by the self-reported quality of life questionnaire SF-36",
            "SecondaryOutcomeTimeFrame": "3, 6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Clinical outcome (WOMAC)",
            "SecondaryOutcomeDescription": "To assess the extent by which a person's functional level is restricted by the WOMAC index",
            "SecondaryOutcomeTimeFrame": "3, 6 and 12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\n18 to 50 years of age (male and female)\nOsteonecrosis of the hip ARCO grade I or II\nAbscence of systemic or local infection\nLaboratory tests with no relevant abnormal findings that contraindicate the surgery.\nInformed Consent Form signed\nThe patient is able to understand the nature of the study\n\nExclusion Criteria:\n\nOsteonecrosis of the hip secondary to femoral neck fracture\nPatients with no closed cartilage\nSurgical implants in the femoral head\nSeptic arthritis\nPatients with severe renal insufficiency\nPatients expecting or with liver transplantation\nPositive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) or Syphilis.\nPregnant woman or intended to become pregnant, or breath feeding\nNeoplasia within the previous 5 years, or without remission\nImmunosuppressive states\nThe patient is legally dependent\nParticipation in another clinical trial or treated with an investigational medicinal product the previous 30 days\nCardiac pacemaker, allergy to contrast or any other condition that contraindicates the MRI with contrast agents\nOther pathologic conditions or circumstances that difficult participation in the study according to medical criteria\nThe patient does not accept to be followed-up for a period thar could exceed the clinical trial length",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "50 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "M√†rius Aguirre, MD, PhD",
            "OverallOfficialAffiliation": "Hospital Vall d'Hebron",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital Universitari Vall d'Hebron",
            "LocationCity": "Barcelona",
            "LocationZip": "08035",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "25769789",
            "ReferenceType": "derived",
            "ReferenceCitation": "Vives J, Oliver-Vila I, Pla A. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. Cytotherapy. 2015 Aug;17(8):1009-14. doi: 10.1016/j.jcyt.2015.02.002. Epub 2015 Mar 10. Review."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Banc de Sang i Teixits. Xcelia-Divisi√≥n de Terapias Avanzadas.",
            "SeeAlsoLinkURL": "http://www.bancsang.net/"
          },
          {
            "SeeAlsoLinkLabel": "Hospital Universitari Vall d'Hebron, Barcelona",
            "SeeAlsoLinkURL": "http://www.vhebron.net/"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010020",
            "ConditionMeshTerm": "Osteonecrosis"
          },
          {
            "ConditionMeshId": "D000007873",
            "ConditionMeshTerm": "Legg-Calve-Perthes Disease"
          },
          {
            "ConditionMeshId": "D000005271",
            "ConditionMeshTerm": "Femur Head Necrosis"
          },
          {
            "ConditionMeshId": "D000009336",
            "ConditionMeshTerm": "Necrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000001847",
            "ConditionAncestorTerm": "Bone Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11436",
            "ConditionBrowseLeafName": "Necrosis",
            "ConditionBrowseLeafAsFound": "Necrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4278",
            "ConditionBrowseLeafName": "Bone Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12095",
            "ConditionBrowseLeafName": "Osteonecrosis",
            "ConditionBrowseLeafAsFound": "Osteonecrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10037",
            "ConditionBrowseLeafName": "Legg-Calve-Perthes Disease",
            "ConditionBrowseLeafAsFound": "Osteonecrosis of the Femoral Head",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7561",
            "ConditionBrowseLeafName": "Femur Head Necrosis",
            "ConditionBrowseLeafAsFound": "Avascular Necrosis of Femur Head",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3358",
            "ConditionBrowseLeafName": "Legg-Calve-Perthes Disease",
            "ConditionBrowseLeafAsFound": "Osteonecrosis of the Femoral Head",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}